CN101428034B - 具有增效减毒特点的抗肿瘤组合药物 - Google Patents
具有增效减毒特点的抗肿瘤组合药物 Download PDFInfo
- Publication number
- CN101428034B CN101428034B CN2008102198789A CN200810219878A CN101428034B CN 101428034 B CN101428034 B CN 101428034B CN 2008102198789 A CN2008102198789 A CN 2008102198789A CN 200810219878 A CN200810219878 A CN 200810219878A CN 101428034 B CN101428034 B CN 101428034B
- Authority
- CN
- China
- Prior art keywords
- arteannuin
- derivant
- teniposide
- cell
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102198789A CN101428034B (zh) | 2008-12-12 | 2008-12-12 | 具有增效减毒特点的抗肿瘤组合药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102198789A CN101428034B (zh) | 2008-12-12 | 2008-12-12 | 具有增效减毒特点的抗肿瘤组合药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101428034A CN101428034A (zh) | 2009-05-13 |
CN101428034B true CN101428034B (zh) | 2012-02-08 |
Family
ID=40643804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008102198789A Expired - Fee Related CN101428034B (zh) | 2008-12-12 | 2008-12-12 | 具有增效减毒特点的抗肿瘤组合药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101428034B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101940569B (zh) * | 2009-07-07 | 2013-02-13 | 鼎泓国际投资(香港)有限公司 | 含有索拉非尼和青蒿素及青蒿素类衍生物的药物组合物及其在制备治疗癌症的药物中的应用 |
TWI482621B (zh) * | 2009-12-23 | 2015-05-01 | Sigma Tau Ind Farmaceuti | 青蒿素基藥物與其他化學治療劑的抗癌組合物 |
CN109481454B (zh) * | 2018-11-22 | 2021-04-30 | 中国中医科学院中药研究所 | 抗肿瘤组合物及其在制备抗肿瘤或抑制癌细胞药物方面的应用、抗肿瘤药物 |
-
2008
- 2008-12-12 CN CN2008102198789A patent/CN101428034B/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
艾辉胜等.替尼泊苷为主的联合方案治疗难治性复发性急性白血的疗效及多药耐药基因的表达.军事医学科学院院刊21 4.1997,21(4),265-268. |
艾辉胜等.替尼泊苷为主的联合方案治疗难治性复发性急性白血的疗效及多药耐药基因的表达.军事医学科学院院刊21 4.1997,21(4),265-268. * |
Also Published As
Publication number | Publication date |
---|---|
CN101428034A (zh) | 2009-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wen et al. | Perspectives and controversies regarding the use of natural products for the treatment of lung cancer | |
JP5057987B2 (ja) | 薬草組成物phy906及びその化学療法における使用 | |
CN105963637B (zh) | 隐丹参酮联合姜黄素在制备肿瘤治疗药物中的应用 | |
EP3391893B1 (en) | Pharmaceutical composition for treating leukemia and preparation method thereof | |
CN103357016A (zh) | 治疗耐药性结核病的药物组合物 | |
EP2263668B1 (en) | Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors | |
CN101428034B (zh) | 具有增效减毒特点的抗肿瘤组合药物 | |
CN108524533A (zh) | 一种化合物用作抗肿瘤药物增效剂和逆转剂 | |
CN109350613B (zh) | 一种治疗癌症的姜黄素复方制剂 | |
CN113925867A (zh) | 盐酸决奈达隆联合5-氟尿嘧啶在制备抗肿瘤药物中的应用 | |
CN109481454B (zh) | 抗肿瘤组合物及其在制备抗肿瘤或抑制癌细胞药物方面的应用、抗肿瘤药物 | |
CN105796638B (zh) | 冬凌草甲素联合隐丹参酮在制备白血病治疗药物中的应用 | |
EP1500398B1 (en) | Herbo-mineral formulation for refractory leukemias and lymphomas | |
KR102578970B1 (ko) | 2,3,5-치환된 싸이오펜 화합물의 난소암 예방, 개선 또는 치료 용도 | |
Liu et al. | Scutellaria baicalensis enhances 5-fluorouracil-based chemotherapy via inhibition of proliferative signaling pathways | |
CN110613716B (zh) | 一种用于治疗癌症的药物组合物及其应用 | |
US20200375943A1 (en) | Cytocidal method of cancer cells selectively in human patients clinically by depletion of l-ascorbic acid, primarily, with its supplementation alternately augmenting its cytocidal effect | |
CN113117087A (zh) | 一种药物组合物及其应用 | |
WO2011160684A1 (en) | Use of uleine for the prevention and/or the treatment of infectious diseases | |
WO2021006822A1 (en) | Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy | |
CN110559287A (zh) | 一种用于治疗癌症的药物组合物及其应用 | |
CN107582561B (zh) | 圣草次苷和七叶树苷在制备抗肿瘤药物中的用途 | |
TWI542347B (zh) | The use of arctigenin for the preparation of anticancer agents | |
CN102440994A (zh) | 灵芝酸g在肿瘤治疗中作为免疫增效剂和超抗原依赖的治疗药物的应用 | |
CN109846876B (zh) | 木脂素类化合物在抗肿瘤中的应用及其药物制备 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU YUNZHONG BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: GUANGZHOU YUNZHONG INVESTMENT DEVELOPMENT CO., LTD. Effective date: 20121224 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20121224 Address after: Panyu District City, Guangzhou City, 511400 North Street Bridge in Guangdong Province along the 39 Lane Street No. 13 2 floor Room 203 Patentee after: Guangzhou Yunzhong Biotechnology Co., Ltd. Address before: Panyu District City, Guangzhou City, 511400 North Street Bridge in Guangdong Province along the 39 Lane Street No. 13 Patentee before: Guangzhou Yunzhong Investment Development Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120208 Termination date: 20191212 |